Pfizer Inc. $PFE Shares Acquired by California Public Employees Retirement System

California Public Employees Retirement System increased its position in Pfizer Inc. (NYSE:PFE) by 9.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 16,723,447 shares of the biopharmaceutical company’s stock after purchasing an additional 1,509,909 shares during the period. California Public Employees Retirement System owned 0.29% of Pfizer worth $426,113,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Norges Bank purchased a new position in shares of Pfizer during the second quarter worth approximately $2,270,157,000. Fisher Asset Management LLC increased its holdings in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Legal & General Group Plc raised its position in Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after purchasing an additional 3,296,415 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Stock Down 1.0%

Shares of Pfizer stock opened at $26.60 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a fifty day moving average of $26.50 and a two-hundred day moving average of $25.52.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.